Abstract
Roche develops, manufactures and markets high-quality products and services in the field of health care. The activities of the group’s four divisions- pharmaceuticals, diagnostics, vitamins and fine chemicals, fragrances and flavors - focus on the prevention, diagnosis and treatment of disease and on the promotion of general well-being.
This case study has been authored by Dr. Peter Borgulya, Pharma Research, Hoffmann-La Roche Ltd., Basel, Switzerland. This case study was written in 1998: The reader should keep in mind that all numbers, figures, organization charts and forecasts represent the state of 1998 or before. The case study was revised in 2007 by Fredrik Ullman.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Reference
Between 1995 and 2000 the cumulative success rate from “Start of Development” through launch was 14%, this number decreased to 8% between 2000 and 2002. (In-vivo: The business & Medicine Report, Bain Drug economics model, in Parexel’s pharmaceutical R&D Statistical Sourcebook 2005/2006 p.111).
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2008). Hoffmann-La Roche: Global Differentiation between Research and Development. In: Managing Global Innovation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68952-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-540-68952-2_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-25441-6
Online ISBN: 978-3-540-68952-2
eBook Packages: Business and EconomicsBusiness and Management (R0)